Know Cancer

or
forgot password

A Phase I Study of Immunotherapy With hA20 Administered Once Weekly for 4 Consecutive Weeks in Patients With CD20+ Non-Hodgkin's Lymphoma


Phase 1/Phase 2
18 Years
N/A
Not Enrolling
Both
Non-Hodgkin's Lymphoma

Thank you

Trial Information

A Phase I Study of Immunotherapy With hA20 Administered Once Weekly for 4 Consecutive Weeks in Patients With CD20+ Non-Hodgkin's Lymphoma


Inclusion Criteria:



- CD20+ B-cell non-Hodgkin's lymphoma (NHL) with measurable disease

Type of Study:

Interventional

Study Design:

Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

Safety and tolerance of different dose levels

Outcome Time Frame:

12 weeks

Safety Issue:

Yes

Principal Investigator

William Wegener, MD, PhD

Investigator Role:

Study Chair

Investigator Affiliation:

Immunomedics, Inc.

Authority:

United States: Food and Drug Administration

Study ID:

IM-T-hA20-01

NCT ID:

NCT00285428

Start Date:

September 2004

Completion Date:

October 2007

Related Keywords:

  • Non-Hodgkin's Lymphoma
  • treatment
  • NHL
  • CD20+ B-cell NHL
  • Lymphoma
  • Lymphoma
  • Lymphoma, Non-Hodgkin

Name

Location

MD Anderson Cancer CenterHouston, Texas  77030-4096
New York Presbyterian Hospital/Cornell Medical CenterNew York, New York  10021
University Hospital of PennsylvaniaPhiladelphia, Pennsylvania  19104